Treatment with HD IL-2 in patients with metastatic melanoma has demonstrated an ORR up to 15%, with approximately 5% of patients developing a CR and a part of the responders showing durable long-term responses [59]. This evidence concerns the gene IL2 and metastatic melanoma.